参考文献

  1. NeuroStar Prescribing Information.
  2. World Health Organization.  Depression fact sheet No.369.  http://www.who.int/mediacentre/factsheets/fs369/en/index.html.  2013 年2 月27 日アクセス
  3. World Health Organization.  The global burden of disease: 2004 update.  http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. 2013 年3 月12 日アクセス
  4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).
  5. Janicak PG, et al. (2008).  Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment.  J Clin Psychiatry, 69(2):222-232.
  6. Data on file.  Neuronetics, Inc.
  7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.
  8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.
  9. Carpenter LL, et al.  (2012).  Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice.  Depress Anxiety, 29(7):587-596.
  10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.
  11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.
  12. Janicak PG, et al. (2010).  Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.  Brain Stimulation, 3(4):187-199.
  13. Demitrack MA, Thase ME. (2009).  Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol  Bull, 42(2):5-38.
  14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526.
  15. World Health Organization.  The World Health Report 2001:  Mental Health:  New Understanding, New Hope.  www.who.int/whr/2001/en/whr01_en.pdf. 2013 年3 月12 日アクセス
  16. Kessler, RC et al. (2003).  Epidemiology of major depressive disorder:  results from the National Comorbidity Survey Replication (NCS-R).  JAMA, 289:3095-3105.
  17. World Health Organization.  The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines.  www.who.int/classifications/icd/en/bluebook.pdf.  2013 年3 月12 日アクセス